Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Renna

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 1, 2020
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitisFabio Salvatore Macaluso, Marco Ventimiglia, Walter Fries, et al.
Journal of Crohn'S & Colitis|March 18, 2014
Early post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohortAmbrogio Orlando, Filippo Mocciaro, Sara Renna, et al.
Drugs & Aging|February 5, 2020
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)Serena Porcari, Anna Viola, Ambrogio Orlando, et al.
Journal of Gastroenterology and Hepatology|May 6, 2023
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's diseaseFabio Salvatore Macaluso, Mauro Grova, Filippo Mocciaro, et al.
Inflammatory Bowel Diseases|April 6, 2022
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19Fabio Salvatore Macaluso, Alessandra Giuliano, Walter Fries, et al.
Journal of Gastroenterology and Hepatology|June 21, 2021
SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501Fabio Salvatore Macaluso, Maria Cappello, Anita Busacca, et al.
Journal of Crohn'S & Colitis|October 9, 2018
A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel DiseaseFabio Salvatore Macaluso, Walter Fries, Antonio Carlo Privitera, et al.
Journal of Crohn'S & Colitis|March 3, 2016
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD StudyLivia Biancone, Alessandro Armuzzi, Maria Lia Scribano, et al.
Cancers|February 15, 2022
Incident Colorectal Cancer in Inflammatory Bowel DiseaseBenedetto Neri, Maria Lia Scribano, Alessandro Armuzzi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 21, 2013
Adalimumab in active ulcerative colitis: a "real-life" observational study, Alessandro Armuzzi, Livia Biancone, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 1, 2020
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitisFabio Salvatore Macaluso, Marco Ventimiglia, Walter Fries, et al.
Journal of Crohn'S & Colitis|March 18, 2014
Early post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohortAmbrogio Orlando, Filippo Mocciaro, Sara Renna, et al.
Drugs & Aging|February 5, 2020
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)Serena Porcari, Anna Viola, Ambrogio Orlando, et al.
Journal of Gastroenterology and Hepatology|May 6, 2023
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's diseaseFabio Salvatore Macaluso, Mauro Grova, Filippo Mocciaro, et al.
Inflammatory Bowel Diseases|April 6, 2022
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19Fabio Salvatore Macaluso, Alessandra Giuliano, Walter Fries, et al.
Journal of Gastroenterology and Hepatology|June 21, 2021
SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501Fabio Salvatore Macaluso, Maria Cappello, Anita Busacca, et al.
Journal of Crohn'S & Colitis|October 9, 2018
A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel DiseaseFabio Salvatore Macaluso, Walter Fries, Antonio Carlo Privitera, et al.
Journal of Crohn'S & Colitis|March 3, 2016
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD StudyLivia Biancone, Alessandro Armuzzi, Maria Lia Scribano, et al.
Cancers|February 15, 2022
Incident Colorectal Cancer in Inflammatory Bowel DiseaseBenedetto Neri, Maria Lia Scribano, Alessandro Armuzzi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 21, 2013
Adalimumab in active ulcerative colitis: a "real-life" observational study, Alessandro Armuzzi, Livia Biancone, et al.
Pageof 7